Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930

NCT ID: NCT05207761

Last Updated: 2023-01-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-19
• Study Completion Date: 2022-11-02

Brief Summary

This study is a randomized, open-label, 2-period, parallel group, multiple-dose phase 1 study to evaluate drug-drug Interaction, safety and tolerability in case of the co-administration of D565 and D930, in healthy male subjects

Detailed Description

To healthy male subjects of thirty-two (32), Investigational products are administered following treatments in each period

Conditions

Glaucoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sequence 1

1. Period 1: D565 7days

2. Period 2: D565+D930 91days

Group Type: EXPERIMENTAL

D565

Intervention Type: DRUG

Q.D. in both eye

D930

Intervention Type: DRUG

T.I.D in both eye

Sequence 2

1. Period 1: D930 91days

2. Period 2: D565+D930 7days

Group Type: EXPERIMENTAL

D565

Intervention Type: DRUG

Q.D. in both eye

D930

Intervention Type: DRUG

T.I.D in both eye

Interventions

D565

Q.D. in both eye

Intervention Type: DRUG

D930

T.I.D in both eye

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy adults volunteers aged between 19 and 55 years old at the time of screening

2. Weight ≥ 55 kg, Calculated Body Mass Index(BMI) of 18.0 to 30.0 kg/m2

• BMI = Weight(kg)/ Height(m)2

3. Individuals who sign an informed consent form and decide to participate in the study after being fully informed of the study prior to participation

4. Individuals who are suitable as a subject for this study at the discretion of the researcher as a result of screening tests such as examination, laboratory tests and questionnaires

Exclusion Criteria

1. Individuals who have other clinically significant cardiovascular system, respiratory system, liver, renal, nervous system, endocrine system, blood-oncology, psychiatric disorders, urinary system or ophthalmic diseases or have a history

2. Individuals who satisfy the following items during the interview or examination

• Individuals with a history of or sign or symptoms of a disease of the visual system
• Individuals who had an ophthalmic surgery including for refractive correction surgery such as LASIK.
• Individuals with corrected visual acuity of 20/40 or less
• Individuals who have experienced side effects after wearing contact lenses or who have worn contact lenses within the last month
• Individuals who have more than 21mmHg or less than 10mmHg on either side of the intraocular pressure test
• Individuals who show abnormal findings in other ophthalmic examinations

3. Individuals who have a history of hypersensitivity to the active ingredient and component of the investigational drug, or to the drug in the same class as the active ingredient

4. Individuals with sitting systolic blood pressure ≥ 140 mmHg or ≤ 80 mmHg or sitting diastolic blood pressure ≥ 90 mmHg or ≤ 45 mmHg

5. Individuals with the following results at screening test

• AST, ALT, γ-GT > 2x the upper limit of the normal range
• Total bilirubin > 2.0 mg/dL
• eGFR(CKD-EPI) < 60 mL/min/1.73m2

6. Individuals who continue to drink(over 21 units/week) within 1 month or cannot abstain from alcohol during the clinical trial period

7. Individuals who tested positive in an alcohol breath analysis

8. Individuals who continuously smoke within one month(including e-cigarettes, over 10 fees/day) or who cannot quit smoking during the clinical trial period;

9. Individuals who cannot restrict the intake of grapefruit or grapefruit-containing food from 3 days before administration of investigational drugs to the final pharmacokinetic blood sample collection

10. Individuals who tested positive for urine cotinine at screening test

11. Individuals who took ethical(ETC) or oriental medicine within 2 weeks or over the counter(OTC) within 1 week before the expected first dose

12. Individuals taking medication known to significantly induce or inhibit drug metabolizing enzymes within 1 month before the expected first dose

13. Individuals with a medical history of significant drug abuse or positive for abuse drug in urine test results at screening

14. Individuals who had been administered investigational product(s) of other clinical study within the 6 months prior to the first dose of this study

15. Individuals who donated whole blood within the 2 months, or donated blood components within 1 month, or received a blood transfusion with 1month prior to the first dose or plan to donate blood or transfusion during the clinical trial period

16. Individuals who are unable to use an appropriate medically approved method of contraception for themselves, their spouses, or partners during the entire clinical trial period and for at least 90 days after the last investigational drug administration and cannot donate sperm during this period

17. Individuals who were deemed to be inappropriate to participate in the study by the investigator

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Seoul National University College of Medicine and Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

A71_05DDI2114

Identifier Type: -

Identifier Source: org_study_id